Clinical Trial

GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
View on ClinicalTrials.gov →
Summary
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2022-02-10; most recent amendment 2026-02-03.
Status change: Not Yet Recruiting → Recruiting 2022-06-22
Trial Details
NCT Number NCT05236114
Lead Sponsor Tempus AI
Collaborators: AstraZeneca
Conditions Non-Small Cell Lung Cancer
Enrollment 1,200 participants
Start Date 2022-06-22
Primary Completion 2029-06 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-02-05